Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHJ002 in progressive myopia in children
NCT06579287Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Countries
- 2
- Sponsor
- Sunhawk Vision Biotech, Inc.
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Drugs
- SHJ002
- Conditions
- myopia
01
Overview
Phase 2, randomised trial of SHJ002 in myopia (2 arms), sponsored by Sunhawk Vision Biotech, Inc. Primary endpoint: Cycloplegic Spherical Equivalent at 52 weeks. Started Jan 2025; status: active, not recruiting.
02
Design
2 arms- Study design
- Randomized
SHJ002
Experimental antisense oligonucleotide ophthalmic solution
Atropine
Active comparator ophthalmic solution
03
Who it enrols
Children aged 3-12 years with progressive myopia (cycloplegic sphere -1.00 D or worse), axial length ≤26 mm, astigmatism ≤2.00 D, normal intraocular pressure, no prior ocular surgery or significant ocular pathology
04
Endpoints
Primary
Cycloplegic Spherical Equivalent
Secondary
Axial Length
Beyond the preview
Go deeper on NCT06579287.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06579287.